[go: up one dir, main page]

WO2009116061A2 - Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine - Google Patents

Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine Download PDF

Info

Publication number
WO2009116061A2
WO2009116061A2 PCT/IN2009/000009 IN2009000009W WO2009116061A2 WO 2009116061 A2 WO2009116061 A2 WO 2009116061A2 IN 2009000009 W IN2009000009 W IN 2009000009W WO 2009116061 A2 WO2009116061 A2 WO 2009116061A2
Authority
WO
WIPO (PCT)
Prior art keywords
aluminium
pharmaceutically acceptable
atorvastatin
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000009
Other languages
English (en)
Other versions
WO2009116061A3 (fr
Inventor
Senapati Manoj
Ranjan Manas
Agarwala Udit
V. Satyanarayana
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkem Laboratories Ltd
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of WO2009116061A2 publication Critical patent/WO2009116061A2/fr
Publication of WO2009116061A3 publication Critical patent/WO2009116061A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt. More particularly it relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and suitable aluminium compounds in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • Atorvastatin calcium an HMG-CoA reductase inhibitor, disclosed in the U. S. Pat. No. 5,273,995, is currently sold in United States of America as Lipitor® having chemical name [R-(R*, R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-( 1 -methylethyl)-3-phenyl-4- [(phenylamino) carbonyl]lH-pyrrole-l-heptanoic acid, calcium salt (2:1) trihydrate. It is indicated for prevention of cardiovascular disease and hypercholesterolemia. Atorvastatin is susceptible to a low pH environment and can degrade to the corresponding lactone in an acidic environment.
  • Amlodipine besylate a long-acting calcium channel blocker is chemically described as 3- Ethyl-5- methyl ( ⁇ )-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)- 1 ,4-dihydro-6- methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate.
  • Amlodipine may readily be prepared as described in U.S. Pat. No. 4,572, 909.
  • Amlodipine besylate, which is currently sold as Norvasc®, may be prepared as described in U.S. Pat. No. 4,879,303, which is incorporated herein by reference.
  • Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.
  • a combination of amlodipine besylate and atorvastatin calcium tablets is available as CADUET® tablets in the United States of America. This combination is indicated in treatment of cardiovascular disease, hypercholesterolemia, hypertension and Coronary Artery Disease (CAD).
  • CAD Coronary Artery Disease
  • U.S. Patent No. 5,686,104 discloses that HMG-CoA reductase inhibitors in an oral pharmaceutical composition for the treatment of hypercholesterolemia or hyperlipidemia areVabilized by combination with at least one alkaline earth metal salt such as calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate or aluminium magnesium hydroxide,
  • alkaline earth metal salt such as calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate or aluminium magnesium hydroxide
  • U.S. Patent No. 6,680,341 discloses a stabilized pharmaceutical formulation containing as an active ingredient an HMG-CoA reductase inhibitor, and a buffering agent, wherein the active composition has a pH in the range from 7 to 11; at least one constituent selected from the group consisting of a filler, a binder, a disintegrating agent and a glidant; and additional buffering agent, wherein ⁇ the pharmaceutical formulation has a pH below 9.
  • U.S. Patent No. 6558659 discloses stabilized pharmaceutical composition for the treatment of dyslipidemia, comprising an active component consisting essentially of one or more compounds selected from the group consisting of (i) a ring-opened 7-substituted- 3,5-dihydroxyheptafloic acid or a pharmaceutically acceptable acid salt thereof, and (ii) a ring-opened 7-substituted-3,5-dihydroxyheptenoic acid or a pharmaceutically acceptable acid salt thereof, and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof, wherein said stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.
  • U.S. Patent No. 6531507 discloses a composition comprising a homogeneous mixture of a HMG-CoA reductase inhibitor with a buffering substance or a basifying substance in a finely distributed form, obtained by co-crystallization and/or co-precipitation of said HMG-CoA reductase inhibitor and said buffering substance or basifying substance.
  • the basifying substance used for co-crystallization and/or co-precipitation is selected from the group consisting of metal oxides, inorganic bases, organic bases and organic ac ⁇ ds with basic character.
  • U.S. Patent Application No. 2003175338 discloses a pharmaceutical formulation comprising atorvastatin and an alkali metal salt additive, the 1 alkali metal salt additive being present at a concentration of between approximately 1.2% and less than 5% by weight of the formulation.
  • PCT Application No. 2005011737 discloses combination of at least one therapeutic agent which is susceptible to degradation, and at least one stabilizing agent comprising at least one carbonate salt of an amino acid, wherein at least in the case where the therapeutic agent is a HMG-CoA reductase inhibitor, or an ACE inhibitor, the stabilizing agent further comprises one or more saccharides, whereby said stabilizing agent can provide a protective stabilizing effect for said therapeutic agent susceptible to degradation when present in a pharmaceutical formulation.
  • PCT Application No. 200600602 IA discloses a stabilized pharmaceutical composition
  • a stabilized pharmaceutical composition comprising a therapeutically effective amount of one or more active pharmaceutical ingredients capable of degradation in a low pH environment and a stabilizing effective amount of one or more amino-group containing monomelic compounds and or amido- group containing monomelic compounds for the stabilization of the active pharmaceutical ingredient.
  • the amino- group containing monomelic compound is selected from the group consisting of . a hydrocarbyl amine, hydroxy substituted hydrocarbyl amine and mixtures thereof.
  • PCT Application No. 2006123358 discloses a stable oral pharmaceutical composition
  • atorvastatin or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier comprising about 0.5 % to about 3.0% by weight of tromethamine and an additional stabilizer in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • the present invention provides a stable oral pharmaceutical composition
  • a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and suitable aluminium compounds in an amount sufficient to prevent -degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • the present invention also provides a stable oral pharmaceutical composition
  • a stable oral pharmaceutical composition comprising a combination of atorvastatin or its pharmaceutically acceptable salt, amlodipine or its pharmaceutically acceptable salt and suitable aluminium compounds in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • the present invention provides a process for preparing a stable oral pharmaceutical composition of atorvastatin or its pharmaceutically acceptable salt comprising mixing atorvastatin or its pharmaceutically acceptable salt with alkaline aluminium salts in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt; and other excipients and converting the mixture into a pharmaceutical composition.
  • a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and alkaline aluminium salts in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • a stable oral pharmaceutical composition comprising a combination of atorvastatin or its pharmaceutically acceptable salt, amlodipine or its pharmaceutically acceptable salt and alkaline aluminium salts in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • C A stable pharmaceutical composition as in A or B above, wherein the atorvastatin or a pharmaceutically acceptable salt thereof is used in amounts ranging from about 0.05 to about 70% w/w of the composition.
  • a stable pharmaceutical composition as in A or B above, wherein the alkaline aluminium salts are used in amounts ranging from about 0.05 to about 70% w/w of the composition.
  • the alkaline aluminium salts are selected from the group comprising aluminium acetate; aluminium chlorhydroxy allantoinate; aluminium diacetate; aluminium hydroxide; aluminium hydroxide - sucrose, hydrated; aluminium oxide; aluminium monostearate; aluminium silicate; aluminium silicate pentahydrate; aluminium starch o
  • a process for preparing a stable oral pharmaceutical composition of atorvastatin or its pharmaceutically acceptable salt comprising mixing atorvastatin or its pharmaceutically acceptable salt with alkaline aluminium salts in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt; and other excipients and converting the mixture into a pharmaceutical composition.
  • the present invention provides a stable oral pharmaceutical composition
  • a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and suitable aluminium compounds in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • the present invention also provides a stable oral pharmaceutical composition
  • a stable oral pharmaceutical composition comprising a combination of atorvastatin or its pharmaceutically acceptable salt, amlodipine or its pharmaceutically acceptable salt and suitable aluminium compounds in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt can be obtained by providing, in a pharmaceutical composition, a stabilizing effective amount of suitable aluminium compounds.
  • stable indicates that when the composition is stored at 40 0 C at 75% relative humidity (RH) in closed containers with or without dessicant for extended period of time such as three months, there is no change in dissolution profile and total impurities percentages do not exceed 3% by weight to the atorvastatin or its pharmaceutically acceptable salt.
  • the present invention is particularly adapted to stable oral pharmaceutical compositions comprising atorvastatin or its pharmaceutically acceptable salt, as the active component of the composition.
  • atorvastatin or its pharmaceutically acceptable salt are metal and amine salts.
  • pharmaceutically acceptable salt thus includes, but is not limited to sodium, potassium, lithium, calcium, magnesium, aluminium, iron and zinc salts of atorvastatin.
  • the atorvastatin is in the form of calcium salt.
  • the atorvastatin or ks pharmaceutically acceptable salt is used in a therapeutically effective amount in the stable oral pharmaceutical compositions of the present Invention.
  • the atorvastatin or its pharmaceutically acceptable salt will generally be present in an amount ranging from about 0.05 to about 70% w/w, preferably in an amount ranging from about 1.0 to about 60% w/w, and most preferably from about 1% to about 40% w/w of the composition.
  • the therapeutic effective amount of atorvastatin or its pharmaceutically acceptable salt that may be used in the stable composition of the present invention is in the range from about 10 to about 100 mg, equivalent to the base.
  • the stable oral pharmaceutical compositions of the present invention may also include amlodipine or its pharmaceutically acceptable salt.
  • pharmaceutically- acceptable acid addition salts is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, besylate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • Other acid addition salts of amlodipine may be, prepared by reacting the free base form of amlodipine with the appropriate acid.
  • the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p- toluenesulfonate, the acetate)
  • the hydrogen form of a dibasic acid e.g., the hydrogen sulfate, the succinate
  • the dihydrogen form of a tribasic acid e.g., the dihydrogen phosphate, the citrate
  • at least one molar equivalent and usually a molar excess of the acid is employed.
  • the appropriate and exact chemical equivalents of acid will generally be used.
  • the free base of amlodipine and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • a particularly preferred salt of amlodipine is the besylate salt.
  • the amlodipine or its pharmaceutically acceptable salt is used in a therapeutically effective amount in the stable oral pharmaceutical compositions of the present invention.
  • the amlodipme or its pharmaceutically acceptable salt may generally be present in an amount ranging from about 0.01 to about 60% w/w, preferably in anamount ranging from about 0.05 to about 40% w/w, and most preferably from about 0.01% to about 20% w/w of the composition.
  • the therapeutic effective amount of amlodipine or its pharmaceutically 'acceptable salt that may be used in the stable composition of the present invention is in the range from about 2.5 to about 20 mg, equivalent to the base.
  • the suitable aluminium compounds are used in an amount sufficient to prevent degradation of the atorvastatin or its pharmaceutically acceptable salt.
  • the suitable aluminium compounds of the invention may be selected from the group comprising aluminium acetate; aluminium chlorhydroxy allantoinate; aluminium diacetate; aluminium hydroxide; aluminium hydroxide - sucrose, hydrated; aluminium oxide; aluminium monostearate; aluminium silicate; aluminium silicate pentahydrate; aluminium starch octenylsuccinate; aluminium stearate; aluminium sulfate; dihydroxyaluminium glycinate; dihydroxyaluminium sodium carbonate; magnesium aluminium silicate; starch aluminium octenyl succinate and the like or mixtures thereof.
  • a preferred suitable aluminium compound of the invention is aluminium hydroxide.
  • the amount of suitable aluminium compounds that may be used in the stable oral pharmaceutical composition of the subject invention ranges from about 0.1 to about 60 % w/w of the composition, more preferably, from about 1% to about 40% w/w of the total weight of the composition,.
  • the pharmaceutical composition of the present invention may further comprise conventional pharmaceutically acceptable excipients.
  • Conventional pharmaceutical' excipients include those which function in a dosage form, for example, as a disintegrant, lubricant, glidant, fillers or diluents, wicking agents, carrier, colorant or coating material
  • the composition of the present invention is formed into tablets.
  • the fillers or diluents that may be used in the stable oral pharmaceutical composition of the present invention include microcrystalline cellulose, mannitol, dextrates, dextrins, dextrose, fructose, lactone, lactitol, maltitol, maltodextrins, maltose and the like and mixtures thereof.
  • a preferred filler is microcrystalline cellulose or lactose or a combination thereof.
  • the diluents or fill ⁇ rs may be used in amounts ranging from about 0.1 to about 80% w/w. It is preferred that the fillers are used in amounts ranging from about 1 to about 70% w/w of the composition.
  • the disintegrants that may be used in pharmaceutical composition of the present invention include carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate, and starch and the like or mixtures thereof.
  • the disintegrants may be used in amounts ranging from about 0.1 to about 50% w/w. It is preferred that the fillers are used in amounts ranging from about 1 to about 20% w/w of the composition.
  • the lubricants used in the present invention may be selected from the group consisting of talc, magnesium stearate, calcium stearate, stearic acid, hy3rogenated vegetable oils, polyethylene glycol and the like and mixtures thereof. Generally the amount of the lubricants used in the present invention may vary from about 0.001 to about 5 % w/w of the composition.
  • the typical glidants that may be included in the present invention include colloidal silicon dioxide, talc and the like.
  • the amounts of glidants used in the present invention may vary from about 0.1 to about 5% w/w of the composition.
  • wicking agents examples include colloidal silicon dioxide, kaolin, titanium dioxide, fumed silicon dioxide, m-pyrol, vinylpyrrolidone polymers such as povidone, or crosslinked polyvinylpyrrolidone such as crospovidone; cellulose and cellulose derivatives such as microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl cellulose, carboxyalicyl celluloses and their alkali salts; sodium starch glycolate, starch and starch derivatives, ion-exchange resins and the like and mixtures thereof.
  • the binders used in the present invention may be selected from the group comprising of starch, gelatin, dextrin, maltocPextrin, natural and synthetic gums like acacia, alginic acid, sodium alginate, guar gum, extract of fish moss, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, # methylcellulose, hydroxyethyl cellulose, hydro oxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, veegum, arabogalactan and the like and mixtures thereof.
  • the film forming polymer used in the the present invention may be selected from the group comprising opadry®, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone; and the like and mixtures thereof.
  • composition of the present invention may also use solubilizers known in the art such as polysorbate 80 and the like; wetting agents known in the art such as sodium lauryl sulfate and the like; and antioxidants known in the art such as butylated hydroxyl anisol, butylated hydroxyl toluene and the like.
  • composition includes solid oral dosage forms such as pellets, beads, granules and the like, which may be encapsulated or compressed into tablets.
  • the pellets, beads, granules in turn may be prepared by conventional methods known to a person skilled in the art.
  • the compressed tablets may optionally be coated with film-coat.
  • compositions of the present invention maybe prepared by the conventional processes such as wet granulation, dry granulation or direct compression.
  • atorvastatin or its pharmaceutically acceptable salt is mixed with suitable aluminium compounds and various excipients and granulated, followed by screening and drying of the damp mass.
  • the dried mass may be screened, lubricated and compressed.
  • Dry granulation can be done by two processes: (1) slugging, which involves mixing the atorvastatin or its pharmaceutically acceptable salt with suitable aluminium compounds and the excipients, slugging, dry screening, lubrication and compression, or (2) roller compaction process.
  • Direct compression involves compressing tablets directly from the physical mixture of atorvastatin or its pharmaceutically acceptable salt, suitable aluminium compounds and the excipients.
  • the pharmaceutical compositions of the present invention may be obtained by preparing placebo granules comprising the suitable aluminium compounds and pharmaceutically acceptable excipients, and mixing these with atorvastatin to obtain a bfend, which may be encapsulated or compressed into tablets. This method" provides compositions of atorvastatin that are stable.
  • the stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt may be prepared as given in Table 1.
  • the atorvastatin calcium, aluminium hydroxide dry gel powder, microcrystalline cellulose, lactose monohydrate and Croscarmellose sodium were sifted through # 40 sieve and mixed for 10 minutes in a RMG.
  • the binder solution was prepared by heating purified water to 40 - 50 0 C and polysorbate 80 added to it with stirring.
  • the Butylated hydroxyl anisol solution dissolved in IPA
  • the previously prepared blend was granulated in RMG using the binder solution prepared above.
  • the granules were dried in rapid drier at 50 C till LOD below 5 % w/w was obtained and sifted through appropriate sieve.
  • croscarmellose sodium was mixed with the above blend.
  • magnesium .stearate was added to the above blend and mixed.
  • the blend was then compressed blend using suitable punches.
  • the tablets were then coated with opadry white ready mix.
  • compositions comprising atorvastatin or its pharmaceutically acceptable salt may be prepared as given in Table 3.
  • compositions were prepared as given as per the procedure given in example 1.
  • compositions comprising atorvastatin or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt may be prepared as given in Table 4.
  • composition was prepared as given as per the procedure given in example 1.
  • the stable oral pharmaceutical compositions comprising atorvastatin or its pharmaceutically acceptable salt may be prepared as given in Table 5.
  • composition of the invention prepared in example 7 was subjected to accelerated studies for 3 months at 40°C/75%RH and dissolution studies for 3 months and the results are shown in Table 7 and Table 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine ou son sel pharmaceutiquement acceptable et des sels d'aluminium alcalins en une quantité suffisante pour prévenir la dégradation de l'atorvastatine ou de son sel pharmaceutiquement acceptable.
PCT/IN2009/000009 2008-01-10 2009-01-05 Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine Ceased WO2009116061A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN78MU2008 2008-01-10
IN78/MUM/2008 2008-01-10

Publications (2)

Publication Number Publication Date
WO2009116061A2 true WO2009116061A2 (fr) 2009-09-24
WO2009116061A3 WO2009116061A3 (fr) 2009-12-17

Family

ID=41091324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000009 Ceased WO2009116061A2 (fr) 2008-01-10 2009-01-05 Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine

Country Status (1)

Country Link
WO (1) WO2009116061A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150372C (fr) * 1993-01-19 2002-08-20 Nancy L. Mills Composition orale stable de ci-981 et procede de preparation
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005115380A2 (fr) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Absorption regulee et localisee de statines dans le tractus gastro-intestinal aux fins de l'obtention de taux sanguins eleves de statines
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine

Also Published As

Publication number Publication date
WO2009116061A3 (fr) 2009-12-17

Similar Documents

Publication Publication Date Title
CN1630510A (zh) 药物形式的阿托伐他汀钙、其组合物和包含阿托伐他汀钙的药物配方
CA2483199A1 (fr) Comprime d'imatinib a forte charge medicamenteuse
EP2494964A1 (fr) Combinaisons de valsartane et d'amlodipine
KR20080094837A (ko) 플루바스타틴 나트륨 약학 조성물
WO2009010787A2 (fr) Compositions stables
EP3793529A1 (fr) Compositions pharmaceutiques stables d'inhibiteurs de dpp-iv en combinaison avec de la metformine sous la forme de comprimés à libération immédiate
KR20140030505A (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
EA030758B1 (ru) Фармацевтические составы на основе вилдаглиптина
EP1978956A1 (fr) Préparation complexe contenant de l'amlopidine camsylate et de la simvastatine, et procédé de production associé
US20120165386A1 (en) Stable oral pharmaceutial composition of atorvastatin
EP1968593B1 (fr) Composition pharmaceutique comprenant de l'acide (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoique
WO2009116061A2 (fr) Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine
US20080260785A1 (en) Paroxetine compositions
CA2612769A1 (fr) Composition pharmaceutique amelioree contenant un inhibiteur de la hmg-coa reductase et procede d'elaboration correspondant
WO2011001450A1 (fr) Composition pharmaceutique orale comprenant de l'atorvastatine
AU2013309686B2 (en) Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
AU2007355452B2 (en) Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof
WO2004091614A2 (fr) Formulations ameliorees de maleate d'amlodipine
EP1810667A1 (fr) Composition pharmaceutique contenant de l'atorvastatin amorphé
WO2009091346A2 (fr) Formulation pharmaceutique stable et procédés de préparation
KR102042626B1 (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2006123358A2 (fr) Composition pharmaceutique orale stable
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
WO2008117154A2 (fr) Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation
EP1911441A2 (fr) Formule de dosage pharmaceutique à couleur stable et à libération contrôlée d'inhibiteurs de réductase HMG-COA, sans agents alcalisants ou tampons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723084

Country of ref document: EP

Kind code of ref document: A2